Stifel raises Elanco Animal Health stock price target to $17 on parasiticide gains

Stifel has increased its price target on Elanco Animal Health (ELAN) to $17.00 from $16.00, maintaining a Buy rating ahead of the company's Q2 2025 results. The firm cited strong parasiticide share gains, improving veterinarian relationships, and a belief that the Street's 2026 constant currency revenue growth estimates are conservative, anticipating 2026 operating margin expansion. This positive outlook aligns with recent upgrades from William Blair and TD Cowen, driven by core business stabilization and a promising innovation pipeline, including a positive EU opinion for its canine allergy treatment Zenrelia. While Leerink Partners expressed cautious optimism due to competition, Elanco has also appointed a new CFO and reaffirmed its guidance, signaling ongoing strategic efforts to enhance its market position.

Analysis

Elanco Animal Health (ELAN) has received a notable vote of confidence from Stifel, which raised its price target to $17.00 from $16.00 and maintained a Buy rating. This optimism is predicated on tangible evidence of market share gains in the parasiticide segment, driven by key products like Credelio Quattro, Advantage, and Seresto. The analysis is further bolstered by improving veterinarian relationships and a conviction that the consensus 4% constant currency revenue growth estimate for 2026 is conservative, with Stifel anticipating the first operating margin expansion in four years. This positive sentiment is echoed by other firms; William Blair upgraded the stock to Outperform, citing core business stabilization and a promising innovation pipeline, while TD Cowen raised its target to $15 based on strong first-quarter results. A significant near-term catalyst is the positive opinion from the European Medicines Agency for Elanco's canine allergy treatment, Zenrelia, which paves the way for EU market authorization. While Leerink Partners offers a more cautious Market Perform rating due to competitive pressures, the collective analyst movement, coupled with a strong 54.89% gross margin, a new CFO appointment, and reaffirmed company guidance, points to a strengthening fundamental picture. Stifel's observation that the stock trades at a discount to peers suggests a potential valuation re-rating if execution on its growth drivers continues.

Key Decisions for Investors

• Given the multiple analyst upgrades and positive momentum from key products and the innovation pipeline, investors may consider the stock's current valuation at a discount to peers as an attractive entry point.
• Investors should closely monitor the upcoming Q2 2025 results for continued parasiticide market share gains and any management commentary that validates Stifel's forecast for operating margin expansion in 2026.
• While the outlook is largely positive, it is prudent to weigh the competitive risks highlighted by Leerink Partners and track the execution and market adoption of new products like Zenrelia to confirm the growth thesis.